Nektar presents rezpegaldesleukin data at dermatology meeting

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) presented data from two Phase 2b studies of rezpegaldesleukin at the 2026 American Academy of Dermatology Annual Meeting in Denver on Friday, according to a company statement. The biotech company’s shares have surged 520% over the past year, trading at $68.66 with a market capitalization of $1.97 billion, though the stock remains unprofitable with a loss of $9.73 per share over the last twelve months.